AACR 2024 | Reducing the need for sentinel node biopsies in cutaneous melanoma

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes findings from a paper assessing the role of sentinel node biopsies for diagnosing primary cutaneous melanoma. The advent of gene expression profiling and immunohistochemistry techniques have reduced the need for invasive biopsies. The Phase III NivoMela trial (NCT04309409) will assess gene expression tests in this setting. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.